The calmodulin binding peptide CBP501 has been reported as an ICD inducer, which promotes calreticulin exposure and HMGB1 release, and increases in vivo mouse survival in vaccination experiments (in combination with cisplatin).Also, the combination of cisplatin and CBP501 also reduces tumour growth and increases intratumoral CD8+ cell infiltration (212). This evidence concerns the gene HMGB1 and neoplasm.